Israel’s Arkin Capital has closed a new $100 million biotech fund, Arkin Bio Ventures III. It will invest in advanced pre- and early- clinical-stage biotech companies developing therapies for areas of high unmet medical need, including oncology, immunology, inflammation and rare diseases.